Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 62 articles:
HTML format



Single Articles


    January 2022
  1. XU L, Zhao B, Butler W, Xu H, et al
    Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.
    Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02155.
    PubMed     Abstract available


  2. CANNISTRACI A, Hascoet P, Ali A, Mundra P, et al
    MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
    Oncogene. 2022 Jan 17. pii: 10.1038/s41388-022-02178.
    PubMed     Abstract available


  3. HAN W, Liu M, Han D, Li M, et al
    RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
    Oncogene. 2022 Jan 3. pii: 10.1038/s41388-021-02135.
    PubMed     Abstract available


    December 2021
  4. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    Correction to: The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02125.
    PubMed    


    November 2021
  5. LEE YC, Lin SC, Yu G, Zhu M, et al
    Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition.
    Oncogene. 2021 Nov 29. pii: 10.1038/s41388-021-02131.
    PubMed     Abstract available


  6. MAZZU YZ, Liao YR, Nandakumar S, Jehane LE, et al
    Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
    Oncogene. 2021 Nov 20. pii: 10.1038/s41388-021-02118.
    PubMed     Abstract available


    October 2021
  7. CHERIF C, Nguyen DT, Paris C, Le TK, et al
    Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
    Oncogene. 2021 Oct 28. pii: 10.1038/s41388-021-02039.
    PubMed     Abstract available


  8. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Oct 19. pii: 10.1038/s41388-021-02060.
    PubMed     Abstract available


  9. HU L, Chen X, Narwade N, Lim MGL, et al
    Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.
    Oncogene. 2021 Oct 5. pii: 10.1038/s41388-021-02026.
    PubMed     Abstract available


    September 2021
  10. LABANCA E, Bizzotto J, Sanchis P, Anselmino N, et al
    Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Oncogene. 2021 Sep 28. pii: 10.1038/s41388-021-02008.
    PubMed     Abstract available


  11. ZHU M, Peng R, Liang X, Lan Z, et al
    P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis.
    Oncogene. 2021 Sep 1. pii: 10.1038/s41388-021-02000.
    PubMed     Abstract available


    August 2021
  12. PARK SH, Fong KW, Mong E, Martin MC, et al
    Going beyond Polycomb: EZH2 functions in prostate cancer.
    Oncogene. 2021 Aug 4. pii: 10.1038/s41388-021-01982.
    PubMed     Abstract available


    July 2021
  13. LIU C, Armstrong CM, Ning S, Yang JC, et al
    ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01914.
    PubMed     Abstract available


    June 2021
  14. HAGIWARA M, Fushimi A, Yamashita N, Bhattacharya A, et al
    MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01899.
    PubMed     Abstract available


  15. LAUNONEN KM, Paakinaho V, Sigismondo G, Malinen M, et al
    Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01887.
    PubMed     Abstract available


  16. PAN T, Lin SC, Lee YC, Yu G, et al
    Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01874.
    PubMed     Abstract available


  17. LIAO Y, Liu Y, Shao Z, Xia X, et al
    A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01851.
    PubMed     Abstract available


    May 2021
  18. LEE HC, Ou CH, Huang YC, Hou PC, et al
    Correction: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01836.
    PubMed    


  19. CRONIN R, Brooke GN, Prischi F
    The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.
    Oncogene. 2021 May 10. pii: 10.1038/s41388-021-01810.
    PubMed     Abstract available


  20. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01805.
    PubMed    


    April 2021
  21. WATSON MJ, Berger PL, Banerjee K, Frank SB, et al
    Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01772.
    PubMed     Abstract available


  22. PUHR M, Eigentler A, Handle F, Hackl H, et al
    Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Oncogene. 2021 Apr 1. pii: 10.1038/s41388-021-01754.
    PubMed     Abstract available


    March 2021
  23. PURAYIL HT, Zhang Y, Black JB, Gharaibeh R, et al
    Nuclear betaArrestin1 regulates androgen receptor function in castration resistant prostate cancer.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01730.
    PubMed     Abstract available


  24. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021 Mar 9. pii: 10.1038/s41388-021-01737.
    PubMed     Abstract available


  25. RIEDEL M, Berthelsen MF, Cai H, Haldrup J, et al
    In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01724.
    PubMed     Abstract available


  26. LEE HC, Ou CH, Huang YC, Hou PC, et al
    YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 Mar 4. pii: 10.1038/s41388-021-01718.
    PubMed     Abstract available


  27. GALBRAITH LCA, Mui E, Nixon C, Hedley A, et al
    PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-021-01707.
    PubMed     Abstract available


    February 2021
  28. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01640.
    PubMed    


  29. MA Y, Zha J, Yang X, Li Q, et al
    Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01667.
    PubMed     Abstract available


  30. LIN C, Blessing AM, Pulliam TL, Shi Y, et al
    Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling.
    Oncogene. 2021 Feb 2. pii: 10.1038/s41388-021-01658.
    PubMed     Abstract available


  31. LIU PI, Chang AC, Lai JL, Lin TH, et al
    Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
    Oncogene. 2021;40:1503-1515.
    PubMed     Abstract available


    January 2021
  32. FORMAGGIO N, Rubin MA, Theurillat JP
    Loss and revival of androgen receptor signaling in advanced prostate cancer.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01598.
    PubMed     Abstract available


  33. YIN L, Li J, Wang J, Pu T, et al
    MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01615.
    PubMed     Abstract available


  34. KWON OJ, Zhang L, Jia D, Xin L, et al
    Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells.
    Oncogene. 2021;40:203-214.
    PubMed     Abstract available


    December 2020
  35. ROGGERO CM, Jin L, Cao S, Sonavane R, et al
    A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01585.
    PubMed     Abstract available


  36. SHARMA S, Pei X, Xing F, Wu SY, et al
    Regucalcin promotes dormancy of prostate cancer.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01565.
    PubMed     Abstract available


    November 2020
  37. HALDRUP J, Strand SH, Cieza-Borrella C, Jakobsson ME, et al
    FRMD6 has tumor suppressor functions in prostate cancer.
    Oncogene. 2020 Nov 28. pii: 10.1038/s41388-020-01548.
    PubMed     Abstract available


  38. BUCKUP M, Rice MA, Hsu EC, Garcia-Marques F, et al
    Plectin is a regulator of prostate cancer growth and metastasis.
    Oncogene. 2020 Nov 20. pii: 10.1038/s41388-020-01557.
    PubMed     Abstract available


  39. SINGH KB, Hahm ER, Kim SH, Wendell SG, et al
    A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.
    Oncogene. 2020 Nov 16. pii: 10.1038/s41388-020-01553.
    PubMed     Abstract available


    October 2020
  40. WANG YA, Sfakianos J, Tewari AK, Cordon-Cardo C, et al
    Molecular tracing of prostate cancer lethality.
    Oncogene. 2020 Oct 12. pii: 10.1038/s41388-020-01496.
    PubMed     Abstract available


  41. BHAGIRATH D, Liston M, Patel N, Akoto T, et al
    MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01493.
    PubMed     Abstract available


    September 2020
  42. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01479.
    PubMed     Abstract available


  43. QIAN K, Wang G, Ju L, Liu J, et al
    A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
    Oncogene. 2020 Sep 25. pii: 10.1038/s41388-020-01476.
    PubMed     Abstract available


  44. LIN SR, Wen YC, Yeh HL, Jiang KC, et al
    EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
    Oncogene. 2020 Sep 22. pii: 10.1038/s41388-020-01468.
    PubMed     Abstract available


  45. WEN S, He Y, Wang L, Zhang J, et al
    Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Oncogene. 2020 Sep 11. pii: 10.1038/s41388-020-01456.
    PubMed     Abstract available


    August 2020
  46. SHAH K, Gagliano T, Garland L, O'Hanlon T, et al
    Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-01429.
    PubMed     Abstract available


  47. WANG Z, Li Y, Wu D, Yu S, et al
    Correction: Nuclear receptor HNF4alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-1290.
    PubMed     Abstract available


  48. SHIN SH, Kim I, Lee JE, Lee M, et al
    Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer.
    Oncogene. 2020 Aug 14. pii: 10.1038/s41388-020-01418.
    PubMed     Abstract available


  49. KO CJ, Hsu TW, Wu SR, Lan SW, et al
    Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis.
    Oncogene. 2020 Aug 10. pii: 10.1038/s41388-020-01413.
    PubMed     Abstract available


    July 2020
  50. KOHNO S, Linn P, Nagatani N, Watanabe Y, et al
    Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
    Oncogene. 2020 Jul 21. pii: 10.1038/s41388-020-1381.
    PubMed     Abstract available


  51. WHITLOCK NC, Trostel SY, Wilkinson S, Terrigino NT, et al
    MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.
    Oncogene. 2020 Jul 17. pii: 10.1038/s41388-020-01389.
    PubMed     Abstract available


    June 2020
  52. NOLLET EA, Cardo-Vila M, Ganguly SS, Tran JD, et al
    Androgen receptor-induced integrin alpha6beta1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
    Oncogene. 2020 Jun 21. pii: 10.1038/s41388-020-1370.
    PubMed     Abstract available


  53. KOHVAKKA A, Sattari M, Shcherban A, Annala M, et al
    AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.
    Oncogene. 2020 Jun 17. pii: 10.1038/s41388-020-1365.
    PubMed     Abstract available


    May 2020
  54. YADAV S, Anbalagan M, Baddoo M, Chellamuthu VK, et al
    Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians.
    Oncogene. 2020;39:4299-4311.
    PubMed     Abstract available


    April 2020
  55. LI M, Nopparat J, Aguilar BJ, Chen YH, et al
    Intratumor delta-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression.
    Oncogene. 2020 Apr 20. pii: 10.1038/s41388-020-1281.
    PubMed     Abstract available


  56. HE Y, Mi J, Olson A, Aldahl J, et al
    Androgen receptor with short polyglutamine tract preferably enhances Wnt/beta-catenin-mediated prostatic tumorigenesis.
    Oncogene. 2020;39:3276-3291.
    PubMed     Abstract available


  57. LI J, Pu T, Yin L, Li Q, et al
    MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
    Oncogene. 2020;39:3305-3321.
    PubMed     Abstract available


    March 2020
  58. ADLER AJ, Mittal P, Hagymasi AT, Menoret A, et al
    GRK2 enforces androgen receptor dependence in the prostate and prostate tumors.
    Oncogene. 2020;39:2424-2436.
    PubMed     Abstract available


    February 2020
  59. LOVERIDGE CJ, Slater S, Campbell KJ, Nam NA, et al
    BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
    Oncogene. 2020;39:1797-1806.
    PubMed     Abstract available


  60. CHEN X, Xiong X, Cui D, Yang F, et al
    DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals.
    Oncogene. 2020;39:1557-1571.
    PubMed     Abstract available


  61. ALI S, Zhang Y, Zhou M, Li H, et al
    Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis.
    Oncogene. 2020;39:1246-1259.
    PubMed     Abstract available


    January 2020
  62. WANG M, Nagle RB, Knudsen BS, Cress AE, et al
    Centrosome loss results in an unstable genome and malignant prostate tumors.
    Oncogene. 2020;39:399-413.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: